# Genoox

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/genoox

- Industry: Biotechnology
- Headquarters: Palo Alto, US
- Website: www.genoox.com/
- Total disclosed funding: $14M
- Latest round: Series B (Jun 1, 2021)
- Investors on record: 6

## About

Genoox, based in the US, specializes in genomic and clinical data solutions, enhancing patient care through its Franklin platform, which integrates real-world genomic insights for healthcare professionals.Genoox, founded in 2014 in Palo Alto, US, focuses on providing genomic and clinical data solutions. The company was established by Amir Trabelsi and Moshe Einhorn. As of May 2025, Genoox was acquired by Qiagen GmbH for USD 70.00 mn in cash, consolidating its position in the genomic data interpretation sector.Genoox specializes in genomic and clinical data solutions through its core platform, Franklin, designed for healthcare professionals. The platform integrates real-world genomic insights with publicly available data, enhancing clinical decision-making and patient care. With over 1,700 organizations across 44 countries utilizing its services, including clinical genetics laboratories and biopharmaceutical companies, Genesis empowers clinicians to utilize its powerful interpretation engine to guide treatment decisions.Genoox generates revenue through a B2B model involving partnerships with healthcare organizations, utilizing its genomic data solutions. The company implements a subscription-based structure for access to the Franklin platform, allowing clients to leverage comprehensive genomic insights. Additionally, it engages in contractual agreements with biopharma companies, offering tailored data services for drug development and targeted therapies.Following its acquisition by Qiagen GmbH in May 2025, Genoox plans to enhance its digital insights offerings for small and mid-sized labs globally by improving NGS data interpretation capabilities. The funding from the acquisition will support these initiatives, enabling Genoox to expand its market presence and develop new products tailored to the evolving needs of healthcare providers.

## Funding rounds

- Series B, Jun 1, 2021, $8M — Glilot Capital Partners, Inimiti, Triventures, IN Venture, Infinitymedicalinc.net
- Series A, Jul 11, 2017, $6M — Glilot Capital Partners, Inimiti
- Seed, Aug 25, 2014 — UpWest

## Investors

- UpWest (https://capitalatlas.ai/funds/upwest) — Seed
- Glilot Capital Partners (https://capitalatlas.ai/funds/glilot-capital-partners) — Series A, Series B
- Inimiti (https://capitalatlas.ai/funds/inimiti) — Series A, Series B
- Triventures (https://capitalatlas.ai/funds/triventures) — Series B
- IN Venture (https://capitalatlas.ai/funds/in-venture) — Series B
- Infinitymedicalinc.net — Series B